How can i add bailey and love 28 edition and srb manual boook to your library to get information according to it
Alright just tell me when to do which investigation in all gallbladder and panreas pathologies
| Situation | Investigation | Rationale |
|---|---|---|
| Suspected gallstones (any patient) | USG abdomen — FIRST LINE | >95% sensitivity; detects stones ≥2 mm, gallbladder wall thickening, pericholecystic fluid |
| Stones not seen on USG but high clinical suspicion | MRCP | Detects small stones, biliary anatomy — no radiation |
| Asymptomatic gallstones | No investigation needed | No workup unless symptomatic |
| Pregnant patient with symptoms | USG only | As accurate as in non-pregnant; safe; no radiation |
| LFTs abnormal + gallstones | Add bilirubin, ALP, GGT, AST, ALT | Screen for choledocholithiasis |
Key rule: USG is diagnostic in cholelithiasis. CT is poor — misses radiolucent cholesterol stones (80% of gallstones are not calcified).
| Situation | Investigation | Rationale |
|---|---|---|
| First investigation | USG abdomen | Murphy's sign on USG + stones + wall thickening (>3 mm) + pericholecystic fluid = diagnostic |
| USG equivocal | HIDA scan (Hepatobiliary scintigraphy) | Failure of GB to visualize = cystic duct obstruction = acute cholecystitis. Sensitivity 97%, specificity 87% |
| Acalculous cholecystitis (ICU patients) | HIDA scan > USG | USG less reliable; HIDA scan more diagnostic |
| Pyrexia, elevated WBC, CRP | CBC, CRP, LFTs | Confirm inflammation, rule out cholangitis |
| CT abdomen | If complications suspected (perforation, empyema, gangrenous cholecystitis) | CT better than USG for complications |
| Situation | Investigation |
|---|---|
| Recurrent biliary colic + stones | USG — confirms stones, wall thickening |
| Acalculous chronic cholecystitis (no stones) | HIDA scan — EF (ejection fraction) <35% on CCK-HIDA = abnormal gallbladder emptying |
| Rule out cancer in porcelain GB | CT abdomen or MRCP |
| ASGE Probability | Clinical Predictors | Action |
|---|---|---|
| HIGH (>50%) | CBD stone on USG, OR clinical cholangitis, OR bilirubin >4 mg/dL | Proceed directly to ERCP (therapeutic + diagnostic) |
| HIGH (>50%) | Dilated CBD (>6 mm with GB in situ) + bilirubin 1.8–4 mg/dL (both present) | Proceed directly to ERCP |
| INTERMEDIATE (10–50%) | Abnormal LFTs (other than bilirubin) + age >55 + dilated CBD | MRCP or EUS first, then ERCP if positive |
| LOW (<10%) | No predictors above | No further biliary workup before cholecystectomy |
| Investigation | When to use |
|---|---|
| USG | First-line — detects dilated CBD (>6 mm), may show stones |
| MRCP | Non-invasive; best for intermediate probability — confirms/excludes stones before ERCP |
| EUS | Equivalent to MRCP; better for stones <5 mm; allows FNA if mass suspected |
| ERCP | High probability or failed MRCP — diagnostic + therapeutic (sphincterotomy, stone extraction) |
| IOCE (Intraoperative cholangiography) | At time of laparoscopic cholecystectomy if intermediate risk |
| Investigation | Role |
|---|---|
| CBC, CRP | WBC <4000 or >10,000; raised CRP — criterion A2 |
| LFTs (ALP, GGT, AST, bilirubin) | Cholestasis criteria — criterion B |
| USG abdomen | Biliary dilatation — criterion C1; may show stone/stricture |
| Blood cultures | Bacteremia in 30–40% — guides antibiotics |
| MRCP / CT | When USG inadequate — show CBD stones, strictures |
| ERCP | Treatment of choice — biliary decompression within 48 hours reduces mortality by 2-fold |
| Stage / Situation | Investigation |
|---|---|
| Incidental finding on USG | CT abdomen + chest for staging |
| Suspected GBC (irregular wall, mass) | USG → CT → MRCP |
| Tissue diagnosis | EUS-guided FNA (for unresectable disease) |
| Resectability assessment | Contrast-enhanced CT (CECT) abdomen — key for vascular involvement, liver invasion, nodes |
| Jaundice present | MRCP or ERCP — assess biliary involvement |
| Tumour markers | CEA + CA 19-9 — elevated in GBC; used for monitoring, not screening |
| Exclude metastases | CT chest + abdomen + pelvis |
Note: PET scan has emerging role in detecting occult metastases in GBC. Laparoscopic staging before open surgery is recommended to exclude peritoneal disease.
| Investigation | When / Role |
|---|---|
| Serum lipase | FIRST LINE — sensitivity ≥85%; more specific than amylase; order alone (no benefit adding both) |
| Serum amylase | Alternative if lipase unavailable; may be normal in late presentation or chronic-on-acute |
| CBC, RFT, LFT, calcium, glucose | Assess severity, identify cause (raised bilirubin = gallstone AP; raised calcium = hypercalcemia) |
| ABG | If PaO₂ <60 mmHg — organ failure criterion |
| USG abdomen | FIRST IMAGING — within 24h to detect gallstones as aetiology; pancreas often obscured by gas |
| CECT abdomen | NOT needed in mild AP; indicated: (a) diagnostic uncertainty, (b) no improvement at 48–72h, (c) suspected complications (necrosis, abscess). Best done at 48–72h not at admission |
| MRCP | If CBD stones suspected but ERCP not yet needed; avoids radiation |
| ERCP | Only when cholangitis coexists with gallstone pancreatitis — within 24–48h. NOT routine in AP |
| Ranson score / APACHE-II / BISAP | Severity scoring at 48h — guides ICU admission |
| CT Severity Index (CTSI) | Done when CECT obtained — grades pancreatic necrosis; CTSI ≥6 = severe |
| HbA1c, triglycerides, IgG4 | To find aetiology: diabetic/hypertriglyceridemia/autoimmune |
Key rule: CT at admission has no advantage over CT at 48–72h. CECT is for complications, not initial diagnosis.
| Situation | Investigation | Role |
|---|---|---|
| First-line workup | CECT abdomen | Calcifications, ductal dilatation, parenchymal atrophy — most specific features |
| Ductal anatomy (before drainage surgery) | MRCP | Best non-invasive assessment of pancreatic duct |
| Exocrine insufficiency assessment | Fecal elastase-1 | <200 μg/g = exocrine insufficiency |
| Endocrine insufficiency | Fasting glucose / HbA1c / OGTT | Pancreatic diabetes (Type 3c) |
| Exclude malignancy in CP | EUS + FNA | Small masses, ductal strictures — biopsy if needed |
| Ductal strictures / stones | ERCP | Therapeutic — ductal drainage, stone extraction |
| Autoimmune pancreatitis (AIP) | IgG4 level | IgG4 >2× normal in Type 1 AIP |
| Hereditary CP workup | PRSS1, SPINK1, CFTR gene testing | In young patients with no apparent cause |
| Situation | Investigation | Role |
|---|---|---|
| Initial investigation | CECT abdomen (pancreatic protocol) | Most important — assesses resectability (SMA, celiac, portal vein involvement) |
| Small lesion (<2 cm) not seen on CT | EUS | Superior to CT for small lesions; detects nodes and vascular involvement |
| Tissue diagnosis (if neoadjuvant chemo planned or unresectable) | EUS-guided FNA / core biopsy | Definitive histology — mandatory before chemotherapy |
| Biliary obstruction | MRCP first, then ERCP if stenting needed | ERCP provides biliary drainage + brush cytology |
| Tumour marker | CA 19-9 | Not diagnostic alone; used for monitoring response and recurrence |
| Metastasis workup | CT chest + abdomen + pelvis | Liver mets, peritoneal disease, lung mets |
| Exclude peritoneal mets before surgery | Staging laparoscopy | Prevents unnecessary laparotomy in ~20% |
| Functional pancreatic tumors | MRI / EUS + octreotide scan (SRS) | Insulinoma, gastrinoma, VIPoma localization |
Key rule: If CT shows a resectable lesion and patient is fit — no tissue biopsy needed before surgery. Biopsy is for unresectable/metastatic/borderline resectable disease.
| Lesion | Investigation |
|---|---|
| Pseudocyst | USG first; CECT for size/extent/complications; MRCP if communication with duct suspected |
| IPMN (Intraductal Papillary Mucinous Neoplasm) | MRCP (best) + EUS; EUS-FNA if high-risk features (wall nodule, dilated MPD >5 mm, jaundice) |
| MCN (Mucinous Cystic Neoplasm) | CECT + MRI/MRCP; CA 19-9 / CEA in cyst fluid (via EUS-FNA) |
| SCN (Serous Cystadenoma) | CT (honeycomb/sunburst pattern); usually no malignant potential — observe |
| Solid Pseudopapillary Neoplasm (SPN) | CT + MRI; young women — surgery is curative |
| Pathology | Best First Investigation | When to escalate |
|---|---|---|
| Cholelithiasis | USG | MRCP if LFTs abnormal |
| Acute Cholecystitis | USG | HIDA scan if equivocal |
| Choledocholithiasis | USG → ASGE risk stratify | MRCP (intermediate) or ERCP (high risk) |
| Acute Cholangitis | LFTs + USG + blood cultures | ERCP within 48h |
| GBC | USG → CECT | MRCP for bile ducts; EUS-FNA for tissue |
| Acute Pancreatitis | Lipase + USG | CECT at 48–72h if no improvement |
| Chronic Pancreatitis | CECT | MRCP for ducts; EUS for malignancy |
| Pancreatic Cancer | Pancreatic protocol CECT | EUS-FNA if tissue needed |
| Cystic lesions | MRCP + CECT | EUS-FNA for fluid analysis |
How to master radiologt with important signs how to identify structures signs explain me like i am your dumbest student
Which radiology modalities do you want to cover? · What is your main goal?
chest X-ray pleural effusion meniscus sign
pneumothorax chest X-ray collapsed lung visceral pleural line
small bowel obstruction X-ray air fluid levels dilated loops